课题基金 / 基金详情

RvD1-FPR2 signaling ameliorates alcoholic liver disease

RvD1-FPR2 signaling ameliorates alcoholic liver disease
RvD1-FPR2信号传导可改善酒精性肝病
批准号:
10160633
负责人:
Josiah E Hardesty
金额:
$6.64万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-05-01 至 2022-11-30

项目摘要

项目成果

Josiah E Hardesty的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Alcoholic hepatitis (AH) is a morbid condition with poor prognosis that is primarily driven by altered immune cell function in response to endotoxemia, but the mechanisms are not fully known or understood. Resolvin D1 (RvD1) is a pro-resolution lipid mediator that signals through formyl peptide receptor 2 (FPR2) in mice eliciting M2 polarization in macrophages and antibacterial functions in neutrophils. Plasma RvD1 levels and hepatic FPR2 expression are decreased in AH patients suggesting this pathway is impeded in AH. Animal models suggest RvD1 treatment ameliorates alcohol induced liver injury, inflammation, fibrosis, and endotoxemia while Fpr2-/- mice develop exacerbated liver injury, inflammation, fibrosis, and endotoxemia. Studies characterizing the RvD1-FPR2 signaling pathway in alcoholic liver disease (ALD) are nonexistent but are warranted based on preliminary data. Aim 1: This aim will determine if RvD1 acts solely through FPR2 to elicit protection in an animal of alcoholic liver disease (ALD). Aim 2: Aim 2a will determine if the RvD1-FPR2 signaling pathway is essential for M2 polarization of Kupffer cells. Aim 2b will establish if RvD1-FPR2 signaling is required for neutrophil-mediated defense responses against pathogenic threats. Aim 3: AH patient and healthy control acquired neutrophils and monocytes will be treated with or without RvD1 ex vivo followed by flow cytometry and proteomic and phosphoproteomic analysis to measure receptor activation and to characterize the signaling pathway, respectively. Collectively this study will generate data that could identify RvD1 or FPR2 agonists as a therapeutic approach for ALD. Due to the severity of AH and the analysis of AH patient samples this study it is immediately impactful and informative for future treatment strategies. Novel biomarkers and therapeutic interventions are expected to come from the conclusion of the proposed study. Basic biology of the RvD1-FPR2 signaling pathway in neutrophils and monocytes is expected from this work as well.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Restoration and preservation of hepatic cardiolipin levels promotes liver regeneration in AH
  • 批准号:
    10708057
  • 项目类别:
  • 资助金额:
    $13.43万
  • 财政年份:
    2022
  • 负责人:
    Josiah E Hardesty
  • 依托单位:
Restoration and preservation of hepatic cardiolipin levels promotes liver regeneration in AH
  • 批准号:
    10572240
  • 项目类别:
  • 资助金额:
    $13.43万
  • 财政年份:
    2022
  • 负责人:
    Josiah E Hardesty
  • 依托单位:
RvD1-FPR2 signaling ameliorates alcoholic liver disease
  • 批准号:
    10380761
  • 项目类别:
  • 资助金额:
    $3.26万
  • 财政年份:
    2020
  • 负责人:
    Josiah E Hardesty
  • 依托单位:
Polychlorinated biphenyls act through EGFR to worsen NAFLD
  • 批准号:
    9328668
  • 项目类别:
  • 资助金额:
    $3.05万
  • 财政年份:
    2017
  • 负责人:
    Josiah E Hardesty
  • 依托单位:
国内基金
海外基金
Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    24.0万元
  • 批准年份:
    2020
  • 负责人:
    乔安娜
  • 依托单位: